Cutaneous melanoma
Therapeutic area
Dermatology
Rare disease
No
- Definition
- A primary melanoma arising from atypical melanocytes in the skin. Precursor lesions include acquired and congenital melanocytic nevi, and dysplastic nevi. Several histologic variants have been recognized, including superficial spreading melanoma, acral lentiginous melanoma, nodular melanoma, and lentigo maligna melanoma.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Cutaneous melanoma
- Therapeutic area
- Dermatology
- cutaneous melanoma
- cutaneous (skin) melanoma
- cutaneous melanoma
- cutaneous melanoma (disease)
- malignant cutaneous melanoma
- malignant melanoma (of skin), stage unspecified
- malignant melanoma of skin
- malignant melanoma of skin stage unspecified
- melanoma (disease) of zone of skin
- melanoma of skin
- melanoma of the skin
- skin melanoma
- skin, melanoma
- zone of skin melanoma
- zone of skin melanoma (disease)
- Disease mechanisms
- Developmental
- Severity
- Severe
- Dermatology
- Oncology
- MONDO ID
- MONDO:0005012
- Parent condition
- MONDO:0002898
Related records
Broader conditions (19)
- Cancer
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disorder of development or morphogenesis
- Human disease
- Integumentary system cancer
- Integumentary system disorder
- Melanocytic neoplasm
- Melanocytic skin neoplasm
- Melanoma
- Neoplasm
- Neoplastic disease or syndrome
- Neurocristopathy
- Skin cancer
- Skin disorder
- Skin neoplasm
Narrower conditions (10)
- Acral lentiginous melanoma
- Amelanotic skin melanoma
- Balloon cell malignant melanoma
- Desmoplastic melanoma
- Eyelid melanoma
- Lentigo maligna melanoma
- Melanoma in congenital melanocytic nevus
- Nodular malignant melanoma
- Spitzoid melanoma
- Superficial spreading melanoma
Trials (186)
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
- 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results
- A Beta-only IL-2 ImmunoTherapY Study
- A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
- A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope)
- A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
- A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma
- A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
- A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
- A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients
- A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
- A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
- A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
- A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
- A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
- A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
- A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
- A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
- A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Approved drugs (14)
- Aldesleukin
- Binimetinib
- Dabrafenib mesylate
- Dacarbazine
- Encorafenib
- Interferon alfa-2B
- Ipilimumab
- Lifileucel
- Nivolumab
- Peginterferon alfa-2B
- Pembrolizumab
- Talimogene laherparepvec
- Trametinib dimethyl sulfoxide
- Vemurafenib
Drugs in development (145)
- .ALPHA.-pyrrolidinononanophenone Phase 3
- 4B5 Phase 1
- 6-O-benzylguanine Phase 2
- Abemaciclib Phase 2
- ABT-510 Phase 2
- Acetaminophen Phase 2
- Acetylcysteine Phase 2
- Aflibercept Phase 3
- Alvocidib Phase 2
- Aspirin Phase 2
- Astuprotimut-R Phase 2
- Atezolizumab Phase 3
- Atorvastatin Phase 2
- Azacitidine Phase 2
- BCG vaccine Phase 2
- Bempegaldesleukin Phase 3
- Bevacizumab Phase 2
- Bleomycin sulfate Phase 1
- Busulfan Phase 1
- Buthionine sulfoximine Phase 1